Tevogen Inc
tevogen.comWhat Do They Do?
Develops off-the-shelf T cell therapies for infectious diseases, cancers and other disorders, including a treatment candidate for coronavirus infection and Long COVID for immunocompromised and high-risk patients.
10-K for FY2025, filed Mar 31, 2026We are a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T…View ↗
The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the…View ↗
We are leveraging our understanding of immunotherapy and our ExacTcell technology to discover, validate, and build a proprietary pipeline…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$5.8MView ↗
- ▲ +5% (Loss)
- vs −$5.5M in Q2 FY2025
-
Apr 22, 2026
Nasdaq notified the company that it no longer met two listing requirements.
Nasdaq gave the company time to regain compliance with both requirements.
Sources
8-K, filed Apr 22, 2026
On April 16, 2026, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of…View ↗
From blank-check company to immunotherapy developer
The older report describes a blank-check company seeking a business combination, focused on transportation, supply chain and logistics. The latest report describes a clinical-stage company developing T cell therapies for infectious diseases, cancers and other disorders.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Mar 31, 2026
Who Do They Compete With?
Competes with OneBlood, Gilead Science, Pfizer, and Invivyd
10-K for FY2025, filed Mar 31, 2026TVGN 489 is being developed to fill the critical gaps that exist in COVID-19 therapeutics for the immunocompromised, the high-risk elderly…View ↗
Loading...
